Effect Insulin Pump Therapy to Patients With Diabetic Nephropathy
Launched by CHINESE PLA GENERAL HOSPITAL · May 31, 2017
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
Worldwidely, about 30% of Type 1 Diabetes Mellitus (T1DM) and 20%-50% of T2DM patients suffered diabetic nephropathy (DN). Oxidative stress resulting from increased production of reactive oxygen species (ROS) plays a crucial role in the development of diabetic complications. Insulin pump therapy is better than subcutaneous injection in terms of the drug safety and effectiveness. The researches aim to monitor the level of oxidative stress of patient in different stage of diabetic nephropathy before and after insulin pump therapy.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diabetic patients with fasting plasma glucose (FPG) ≥10mmol/l and/or 2 hours' plasma glucose (2hPG) ≥15mmol/l.
- Exclusion Criteria:
- • Diabetic patients who
- • 1. using antioxidant drugs within one month;
- • 2. accompanied with acute and chronic severe complications, fever, malignant tumor, nephritis, congestive heart failure.
- • 3. accompanied with diabetic ketosis, ketoacidosis, severe hypoglycemia, hyperosmolar hyperglycemic state;
- • 4. with other endocrine diseases, autoimmune diseases, or connective tissue diseases;
- • 5. having history of infection within 1 month;
- • 6. having drug or alcohol dependence;
- • 7. severe hypoxia and stress state (e.g., cardiovascular events, trauma, surgery, and consumptive disease, etc.)
About Chinese Pla General Hospital
The Chinese PLA General Hospital, a prominent military medical institution in Beijing, serves as a leading sponsor for clinical trials, focusing on advancing healthcare through innovative research and development. Renowned for its comprehensive medical services and cutting-edge research capabilities, the hospital is committed to improving patient outcomes through rigorous scientific investigation and collaboration with various stakeholders in the healthcare sector. With a multidisciplinary approach and a strong emphasis on evidence-based practices, the Chinese PLA General Hospital aims to contribute significantly to the global medical community by facilitating the development of safe and effective therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Min Liu
Study Chair
Center for Drug Evaluation, China food and Drug Administration
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials